Anti-Human Epidermal Growth Factor Receptor-2 Therapies in Biliary Tract Cancers: A Meta-Analysis on Disease Location, Human Epidermal Growth Factor Receptor-2 Status, and Survival Outcomes
Oncology · 26.05.2025 · 104 (3) · 306-318
DOI: 10.1159/000545308 ↗Kurz gefasst
Metaanalyse in der Zeitschrift Oncology, online erschienen am 26.05.2025. Verfasst von Silvia Camera und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, Vita-Salute San Raffaele University, IRCCS San Raffaele Scientific Institute Hospital, Milan, Italy. Hauptthemen laut MEDLINE: Erb-b2 Receptor Tyrosine Kinases, Biliary Tract Neoplasms. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 61 Literaturangaben.
Abstract (Originalsprache)
Introduction
In recent years, the therapeutic scenario of metastatic biliary tract cancers (BTCs) beyond first-line has profoundly changed owing to target therapies. human epidermal growth factor receptor-2 (HER2) represents a promising molecular target that is frequently altered in BTC. The present meta-analyses aimed to describe the response rates and survival outcomes in patients with HER2-positive locally advanced/metastatic BTC treated with anti-HER2 therapies. Moreover, the study is intended to provide an update on the evolving therapeutic scenario of HER2-overexpressed BTC.
Methods
We performed a systematic review of the literature to identify clinical trials investigating any regimen comprising a HER2-targeted therapy for metastatic BTC, and we conducted three subsequent meta-analyses on second-line phase II trials. The first one was performed to compare the group of HER2 3+ versus the group of HER2 2+ BTC patients for objective response rate (ORR). The second one compared patients according to the tumor location (gallbladder carcinoma [GBC] or extrahepatic cholangiocarcinoma [eCCA] versus intrahepatic cholangiocarcinoma [iCCA]) for ORR. The third one evaluated the overall outcomes in terms of overall survival (OS) and progression-free survival (PFS).
Results
Patients with advanced BTC and HER2 3+ had better ORR compared to HER2 2+, with a 3.7-fold higher probability of experiencing objective responses (HR 3.70, 95% CI, 1.34–10.25, p = 0.0119). Likewise, patients with GBC or eCCA had a 2.74-fold higher probability of experiencing an objective response compared to patients with iCCA (HR 2.74, 95% CI, 1.12–6.73, p = 0.0275). The weighted pooled analysis of trials with anti-HER2 agents in second line or beyond revealed an mPFS of 4.9 months (95% CI, 4.2–5.6), while mOS was 10.8 months (95% CI, 9.0–12.8).
Conclusions
Our meta-analyses have revealed improved efficacy in patients with HER2 3+ metastatic BTC and in patients with GBC or eCCA treated with anti-HER2 therapies, with a considerable mPFS and mOS in the overall population of the phase II trials analyzed. Further studies are paramount to confirm our preliminary results.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Oncology, Vita-Salute San Raffaele University, IRCCS San Raffaele Scientific Institute Hospital, Milan, Italy.
- Operative Research Unit of Oncology, Fondazione Policlinico Universitario Campus Bio-Medico, Rome, Italy.
- Medical Oncology, University and University Hospital of Cagliari, Cagliari, Italy.
- Department of Oncology, Vita-Salute San Raffaele University, IRCCS San Raffaele Scientific Institute Hospital, Milan, Italy, casadeigardini@gmail.com.
- San Raffaele Telethon Institute for Gene Therapy (SR-Tiget), IRCCS San Raffaele Scientific Institute Hospital, Milan, Italy.
Zitieren
APA
Camera, S., Rimini, M., Foti, S., Lo Prinzi, F., Vitiello, F., Amadeo, E., Persano, M., Cascinu, S., Casadei-Gardini, A., & Rossari, F. (2025). Anti-Human Epidermal Growth Factor Receptor-2 Therapies in Biliary Tract Cancers: A Meta-Analysis on Disease Location, Human Epidermal Growth Factor Receptor-2 Status, and Survival Outcomes. Oncology, 104(3), 306-318. https://doi.org/10.1159/000545308
Vancouver
Camera S, Rimini M, Foti S, Lo Prinzi F, Vitiello F, Amadeo E, et al. Anti-Human Epidermal Growth Factor Receptor-2 Therapies in Biliary Tract Cancers: A Meta-Analysis on Disease Location, Human Epidermal Growth Factor Receptor-2 Status, and Survival Outcomes. Oncology. 2025;104(3):306-318. doi:10.1159/000545308
BibTeX
@article{Camera2025,
author = {Camera, Silvia and Rimini, Margherita and Foti, Silvia and Lo Prinzi, Federica and Vitiello, Francesco and Amadeo, Elisabeth and Persano, Mara and Cascinu, Stefano and Casadei-Gardini, Andrea and Rossari, Federico},
title = {Anti-Human Epidermal Growth Factor Receptor-2 Therapies in Biliary Tract Cancers: A Meta-Analysis on Disease Location, Human Epidermal Growth Factor Receptor-2 Status, and Survival Outcomes},
journal = {Oncology},
year = {2025},
volume = {104},
number = {3},
pages = {306--318},
doi = {10.1159/000545308}
}
EUVIMED